Oramed Pharmaceuticals (ORMP) Gains from Investment Securities (2011 - 2026)

Oramed Pharmaceuticals has reported Gains from Investment Securities for 15 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Gains from Investment Securities rose 416.67% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.1 million (up 1641.5% YoY), and the FY2025 full-year result was $588514.0, down 67.17% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at $1.5 million, up from -$204000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $7.6 million in Q4 2024, with the low at -$16.2 million in Q4 2023.
• Historically, Gains from Investment Securities has averaged -$411668.8 across 5 years, with a median of $99680.0 in 2022.
• Annual changes were most pronounced in 2024 — Gains from Investment Securities sank 5666.15% — and 2025, when it surged 996.34%.
• Oramed Pharmaceuticals' Gains from Investment Securities stood at $1.9 million in 2022, then tumbled by 945.12% to -$16.2 million in 2023, then soared by 146.62% to $7.6 million in 2024, then sank by 102.7% to -$204000.0 in 2025, then jumped by 844.61% to $1.5 million in 2026.
• The last three Gains from Investment Securities figures came in at $1.5 million (Q1 2026), -$204000.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.